Due to the recent advances in drug, molecular and cell therapies [7]–[9] dystrophinopathies are a field of intense interest in terms of both phenotype stratification and dystrophin gene regulation. The gene discussed is DMD; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.